Currently Viewing
CURE's Clinical Trial Corner: November 2019
November 29, 2019 – Kristie L. Kahl
What Patients With CLL/SLL Should Know About the FDA's Approval of Calquence
November 27, 2019 – Kristie L. Kahl
Exploring the Future of Prostate Cancer with City of Hope
November 27, 2019 – Jessica Skarzynski
New Issue Alert: Lung Cancer Special Issue #2
November 27, 2019 – Katie Kosko and Jessica Skarzynski
'Victories' After Multiple Myeloma
November 26, 2019 – Katie Kosko
Clinical Trial Investigating an Immunotherapy Vaccine for Patients with GBM to Open in 2020
November 26, 2019 – Katie Kosko
CURE's Clinical Trial Corner: MPN Edition
November 26, 2019 – Katie Kosko
Melanoma Education is Key to Saving Lives
November 25, 2019 – Katie Kosko
CURE's Clinical Trial Corner: Mesothelioma Edition
November 25, 2019 – Jessica Skarzynski

CURE's Clinical Trial Corner: November 2019

Here is a list of the recent trial initiations that occurred within the cancer space in November.
BY Kristie L. Kahl
PUBLISHED November 29, 2019
As the cancer treatment landscape continues to grow, patients and their caregivers should be aware of the various clinical trials currently being conducted – and ones they can possibly join.

Head and Neck Cancer
Sensei Biotherapeutics, Inc. announced the dosing of the first patient in its phase 1/2 clinical trial, designed to evaluate SNS-301 – a first-in-class immunotherapy candidate utilizing a bacteriophage viral vector that targets human aspartate β‑hydroxylase (ASPH) –  in patients with ASPH‑positive head and neck cancer who have previously received immune checkpoint inhibitors. The multicenter, open-label trial is evaluating the safety, preliminary efficacy and immunogenicity of SNS-301 in combination with Keytruda (pembrolizumab). The primary efficacy endpoints of the study include objective response rate (complete and partial responses to therapy), duration of response and multiple secondary endpoints measuring immune responses.

The company expects to enroll approximately 30 patients in its two-stage trial. “Targeting ASPH represents a novel strategy for treating cancer and we believe that SNS-301 has potentially broad applicability across a wide variety of cancers with its unique mechanism combined with checkpoint inhibition. We look forward to providing preliminary results at a major medical meeting in 2020,” Dr. Ildiko Csiki, consulting chief medical officer of Sensei Biotherapeutics, said in a press release.

Ovarian Cancer
Celsion Corporation has completed its safety review of data from the first eight patients enrolled in the ongoing phase 1/2 OVATION 2 study and will proceed with completing enrollment in the phase 1 portion of the trial. The trial is designed to evaluate the safety of GEN-1, an IL-12 gene-mediated immunotherapy, in combination with the standard of care for the treatment of newly diagnosed patients with stage 3 and 4 ovarian cancer who will undergo standard neoadjuvant chemotherapy followed by interval debulking surgery.

“OVATION 2 is designed to define the optimal dose of GEN-1 and provide important insights into GEN-1's clinical benefit as an adjuvant therapy both before and after debulking surgery with the potential to stimulate an anticancer immune response, compared to the current standard of care alone,” Dr. Nicholas Borys, executive vice president and chief medical officer of Celsion, said in a press release.

The trial will enroll up to 130 patients with Stage 3/4 ovarian cancer, with 12 to 15 patients in the phase 1 portion and up to 118 patients in the phase 2 portion.

Melanoma
CytomX Therapeutics, Inc. initiated the phase 2 PROCLAIM (Probody Clinical Assessment In Man) CX-072-002 program – designed to evaluate CX-072, an anti-PD-L1 Probody , in combination with Yervoy (ipilimumab), an anti-CTLA-4 antibody, for the treatment of patients with relapsed or refractory melanoma.

The open-label, multi-center phase 2 clinical study will evaluate approximately 40 patients being enrolled into stage 1 of the study, with additional patients being enrolled into stage 2 pending the outcome of the first stage. CytomX anticipates initial data from stage 1 in 2020.

“This exciting study leverages our unique technology platform to enable a more powerful combination therapy directed against the two best validated pathways in immuno-oncology and could represent a significant advance in outcomes for these patients who have few treatment options,” Dr. Amy Peterson, chief development officer of CytomX Therapeutics, said in a press release.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Ovarian Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In